{"id":"W2752227448","doi":"10.1056/nejmoa1709030","title":"Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma","year":2017,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2207,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Medical Research Council; Cancer Research UK","keywords":"Ipilimumab; Nivolumab; Medicine; Melanoma; Adjuvant; Adjuvant therapy; Oncology; Internal medicine; Placebo; Immunotherapy; Chemotherapy; Cancer; Cancer research; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05226193040225233,"score_gpt":0.3429099879807146,"score_spread":0.2906480575784622,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}